Estrogen and progesterone receptor (ER and PR), HER2/ERBB2, and Ki67 expression levels together with tumor–node-metastasis (TNM) staging are the parameters used to stratify patients and guide therapeutic decisions (2). The gene discussed is ERBB2; the disease is neoplasm.